Encouraging pre-clinical observations with novel IGF-1R antagonists (488) and epidemiological surveys linking IGF-1 levels to cancer risk (489), led to many clinical trials with biologicals and small molecules, but with sobering results (360). The gene discussed is IGF1R; the disease is cancer.